Comprehensive Serum Metabolic and Proteomic Characterization on Cognitive Dysfunction in Parkinson's Disease

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2021 May 14

PMID 33987257

Citations 4

Authors

Na Zhang

Chuanxi Tang

Qiong Ma

Wei Wang

Mingyu Shi

Xiaoyu Zhou

Fangfang Chen

Chengcheng Ma

Xue Li

Gang Chen

Dianshuai Gao

Affiliations

Soon will be listed here.

Abstract

Background: Given the increased incidence of Parkinson's disease (PD) and the lack of accurate early diagnosis of PD with cognitive impairment (PD-CI), we compared the serum metabolomes and proteomes of 26 patients with PD without cognitive impairment (PD-N) and 31 patients with PD-CI by combining grade-dependent proteomics and metabolomics analyses.

Methods: Logistic and linear regression analyses were performed for differential metabolic indicators, cognition, and clinical diagnosis. Ingenuity pathway analysis (IPA) was used to identify metabolites linked to different pathways. Bioinformatics revealed 16 differentially expressed proteins and 32 metabolites.

Results: The positive metabolic indicators related to the differential proteins were one sphingolipid, five phosphatidylcholines, and five long-chain fatty acids. The obtained metabolic and proteomics IPA network highlighted the central term of this network was inflammation and abnormal lipid metabolism which are prominent in PD-CI. There was a strong negative correlation between the Mini-Mental State Examination (MMSE)score and LPC (18:1). The receiver operating characteristic (ROC) of LPC (18:1) for PD-N and PD-CI showed that the area under the curve (AUC) value was 0.660 (P=0.039).

Conclusions: In conclusion, serum LPC (18:1) is inversely linked to cognition in PD and presented its potential clinical value in distinguishing the presence or absence of cognitive impairment in PD. The deeper implication of our discovery indicates abnormal lipid metabolism is associated with changes of cognitive status and suggests the potential for possibility of immune system- inflammatory involvement.

Citing Articles

Multi-omics characterization of improved cognitive functions in Parkinson's disease patients after the combined metabolic activator treatment: a randomized, double-blinded, placebo-controlled phase II trial.

Yulug B, Altay O, Li X, Hanoglu L, Cankaya S, Velioglu H Brain Commun. 2025; 7(1):fcae478.

PMID: 39816194 PMC: 11733689. DOI: 10.1093/braincomms/fcae478.

A crazy trio in Parkinson's disease: metabolism alteration, α-synuclein aggregation, and oxidative stress.

Li S, Liu Y, Lu S, Xu J, Liu X, Yang D Mol Cell Biochem. 2024; 480(1):139-157.

PMID: 38625515 DOI: 10.1007/s11010-024-04985-3.

Postpartum Oxytocin Treatment via the Mother Reprograms Long-Term Behavioral Disorders Induced by Early Life Stress on the Plasma and Brain Metabolome in the Rat.

Morley-Fletcher S, Gaetano A, Gao V, Gatta E, Van Camp G, Bouwalerh H Int J Mol Sci. 2024; 25(5).

PMID: 38474260 PMC: 10932010. DOI: 10.3390/ijms25053014.

Serum metabolomic characterization of PLA2G6-associated dystonia-parkinsonism: A case-control biomarker study.

Chen C, Lou M, Sun Y, Luo F, Liu F, Luo S Front Neurosci. 2022; 16:879548.

PMID: 36033628 PMC: 9406281. DOI: 10.3389/fnins.2022.879548.

Serum Metabonomics Reveals Key Metabolites in Different Types of Childhood Short Stature.

Chen G, Wang J, Jing Y, Li C, Zhang W, Yang S Front Pharmacol. 2022; 13:818952.

PMID: 35600884 PMC: 9117746. DOI: 10.3389/fphar.2022.818952.

References

Trezzi J, Galozzi S, Jaeger C, Barkovits K, Brockmann K, Maetzler W . Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease. Mov Disord. 2017; 32(10):1401-1408. DOI: 10.1002/mds.27132. View

Zarrouk A, Debbabi M, Bezine M, Karym E, Badreddine A, Rouaud O . Lipid Biomarkers in Alzheimer's Disease. Curr Alzheimer Res. 2017; 15(4):303-312. DOI: 10.2174/1567205014666170505101426. View

Farooqui A . Lipid mediators in the neural cell nucleus: their metabolism, signaling, and association with neurological disorders. Neuroscientist. 2009; 15(4):392-407. DOI: 10.1177/1073858409337035. View

Hughes A, Daniel S, Blankson S, Lees A . A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol. 1993; 50(2):140-8. DOI: 10.1001/archneur.1993.00540020018011. View

Spiegel S . Sphingosine 1-phosphate: a prototype of a new class of second messengers. J Leukoc Biol. 1999; 65(3):341-4. DOI: 10.1002/jlb.65.3.341. View

Crowell Jr B, Benson R, Shockley D, Charlton C . S-adenosyl-L-methionine decreases motor activity in the rat: similarity to Parkinson's disease-like symptoms. Behav Neural Biol. 1993; 59(3):186-93. DOI: 10.1016/0163-1047(93)90950-m. View

Poewe W, Seppi K, Tanner C, Halliday G, Brundin P, Volkmann J . Parkinson disease. Nat Rev Dis Primers. 2017; 3:17013. DOI: 10.1038/nrdp.2017.13. View

Sheikh A, Nagai A, Ryu J, McLarnon J, Kim S, Masuda J . Lysophosphatidylcholine induces glial cell activation: role of rho kinase. Glia. 2008; 57(8):898-907. DOI: 10.1002/glia.20815. View

Prins M . Cerebral metabolic adaptation and ketone metabolism after brain injury. J Cereb Blood Flow Metab. 2007; 28(1):1-16. PMC: 2857668. DOI: 10.1038/sj.jcbfm.9600543. View

10.

Alves G, Lange J, Blennow K, Zetterberg H, Andreasson U, Forland M . CSF Aβ42 predicts early-onset dementia in Parkinson disease. Neurology. 2014; 82(20):1784-90. DOI: 10.1212/WNL.0000000000000425. View

11.

WELLS I, Peitzmeier G, Vincent J . Lecithin: cholesterol acyltransferase and lysolecithin in coronary atherosclerosis. Exp Mol Pathol. 1986; 45(3):303-10. DOI: 10.1016/0014-4800(86)90019-5. View

12.

Young S, Mina J, Denny P, Smith T . Sphingolipid and ceramide homeostasis: potential therapeutic targets. Biochem Res Int. 2012; 2012:248135. PMC: 3286894. DOI: 10.1155/2012/248135. View

13.

Mapstone M, Cheema A, Fiandaca M, Zhong X, Mhyre T, MacArthur L . Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med. 2014; 20(4):415-8. PMC: 5360460. DOI: 10.1038/nm.3466. View

14.

Cui Y, Liu X, Wang M, Liu L, Sun X, Ma L . Lysophosphatidylcholine and amide as metabolites for detecting alzheimer disease using ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabonomics. J Neuropathol Exp Neurol. 2014; 73(10):954-63. DOI: 10.1097/NEN.0000000000000116. View

15.

Jeong H, Kim Y, Lee Y, Jung S, Oh S . TRPM2 contributes to LPC-induced intracellular Ca influx and microglial activation. Biochem Biophys Res Commun. 2017; 485(2):301-306. DOI: 10.1016/j.bbrc.2017.02.087. View

16.

Maceyka M, Spiegel S . Sphingolipid metabolites in inflammatory disease. Nature. 2014; 510(7503):58-67. PMC: 4320971. DOI: 10.1038/nature13475. View

17.

Robotti A, Natale M, Giuliano Albo A, Lis K, Perga S, Marnetto F . Acute-phase proteins investigation based on lectins affinity capture prior to 2-DE separation: application to serum from multiple sclerosis patients. Electrophoresis. 2010; 31(17):2882-93. DOI: 10.1002/elps.201000171. View

18.

Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M . CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016; 15(7):673-684. DOI: 10.1016/S1474-4422(16)00070-3. View

19.

Lee E, Soliman K, Charlton C . Lysophosphatidylcholine decreases locomotor activities and dopamine turnover rate in rats. Neurotoxicology. 2004; 26(1):27-38. DOI: 10.1016/j.neuro.2004.07.009. View

20.

McDougall M, Choi J, Magnusson K, Truong L, Tanguay R, Traber M . Chronic vitamin E deficiency impairs cognitive function in adult zebrafish via dysregulation of brain lipids and energy metabolism. Free Radic Biol Med. 2017; 112:308-317. PMC: 5629005. DOI: 10.1016/j.freeradbiomed.2017.08.002. View